



HHS Public Access

Author manuscript

Nature. Author manuscript; available in PMC 2016 July 05.

Published in final edited form as:

Nature. 2015 December 3; 528(7580): S68–S76. doi:10.1038/nature16046.

Sustainable HIV Treatment in Africa through Viral Load-Informed Differentiated Care

Andrew Phillips,

Research Department of Infection & Population Health, University College London

Amir Shroufi,

Medecins Sans Frontieres, South Africa & Lesotho

Lara Vojnov,

Clinton Health Access Initiative, Liberia

Jennifer Cohn,

Medecins Sans Frontieres Access Campaign, Geneva, Switzerland

Teri Roberts,

Medecins San Frontieres Access Campaign, Geneva, Switzerland

Tom Ellman,

Medecins San Frontieres, South Africa Medical Unit

Kimberly Bonner,

Medecins San Frontieres Access Campaign, Geneva, Switzerland

Christine Rousseau,

Bill & Melinda Gates Foundation

Geoff Garnett,

Bill & Melinda Gates Foundation

Valentina Cambiano,

Institutional Research Information Service, University College London

Fumiyo Nakagawa,

Institutional Research Information Service, University College London

Deborah Ford,

Institutional Research Information Service, University College London

Loveleen Bansi-Matharu,

Institutional Research Information Service, University College London

Alec Miners,

Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine

Correspondence: Andrew Phillips, Research Department of Infection & Population Health, UCL, London. andrew.phillips@ucl.ac.uk.
*Membership listed in Appendix

Jens Lundgren,

Rigshospitalet, Copenhagen, Denmark

Jeff Eaton,

School of Public Health, Imperial College London

Rosalind Parkes-Ratanshi,

Infectious Diseases Institute, Kampala, Uganda

Zachary Katz,

Clinton Health Access Initiative, New York

David Maman,

Epicentre, Medecins Sans Frontieres, France

Nathan Ford,

World Health Organization

Marco Vitoria,

World Health Organization

Meg Doherty,

World Health Organization

David Dowdy,

Johns Hopkins Bloomberg School of Public Health

Brooke Nichols,

Erasmus Medical Center, Rotterdam, The Netherlands

Maurine Murtagh,

Northwestern Global Health Foundation, Evanston, Illinois

Meghan Wareham,

Clinton Health Access Initiative, New York

Kara Palamountain,

Global Health Initiative, Kellogg School of Management, Northwestern University

Christine Chiedza Musanhu,

World Health Organization

Wendy Stevens,

University of Witwatersrand/National Health Laboratory Service, South Africa

David Katzenstein,

Stanford School of Medicine, Stanford, California

Andrea Ciaranello,

Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts

Ruanne Barnabas,

Department of Global Health, University of Washington, Seattle, Washington

Scott Braithwaite,

Department of Population Health, NYU School of Medicine, New York

Eran Bendavid,

Freeman Spogli Institute for International Studies, Stanford University, Stanford, California

Kusum J Nathoo,

Department of Paediatrics, University of Zimbabwe

David van de Vijver,

Erasmus Medical Center, Rotterdam, The Netherlands

David Wilson,

Global HIV/AIDS Program, The World Bank, London, UK

Charles Holmes,

Centre for Infectious Disease Research in Zambia

Anna Bershteyn,

Institute for Disease Modeling, Bellevue, Washington

Simon Walker,

Centre for Health Economics, University of York

Elliot Raizes,

Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, Georgia

Ilesh Jani,

Instituto Nacional de Saude, Ministry of Health, Mozambique

Lisa Nelson,

PEPFAR, Office of the US Global AIDS Coordinator and Health Diplomacy, US Department of State

Rosanna Peeling,

International Diagnostics Centre, London School of Hygiene & Tropical Medicine

Fern Terris-Prestholt,

Department of Global Health and Development, London School of Hygiene & Tropical Medicine

Joseph Murungu,

National HIV Care & Treatment Program, Ministry of Health and Child Care, Zimbabwe

Tsitsi Mutasa-Apollo,

AIDS and TB Department, Ministry of Health and Child Care, Zimbabwe

Timothy Hallett, and

School of Public Health, Imperial College London

Paul Revill

Centre for Health Economics, University of York

Working Group on Modelling of ART Monitoring Strategies in Sub-Saharan Africa*

Abstract

There are inefficiencies in current approaches to monitoring patients on antiretroviral therapy (ART) in sub-Saharan Africa. Patients typically attend clinics every 1–3 months for clinical assessment, with clinic costs being comparable with costs of drugs themselves, CD4 counts are measured every 6 months, yet patients are rarely switched to second-line therapies. To ensure sustainability of treatment programmes a transition to more cost-effective ART deliver is needed. In contrast to the CD4 count, measurement of the level of HIV RNA in plasma (“viral load”) provides a direct measure of current treatment effect. *Viral load informed differentiated care* is a means of tailoring care whereby those with suppressed viral load have less frequent clinical visits and attention is paid to those with unsuppressed viral load to promote adherence and timely switching to a second-line regimen. The most feasible approach in many countries to measure viral load is by collecting dried blood spot (DBS) samples for testing in regional laboratories, although there have been concerns over the sensitivity/specificity of DBS to define treatment failure and the delay in receiving results. We use modelling to synthesize available evidence and evaluate the cost-effectiveness of *viral load-informed differentiated care*, account for limitations of DBS. We find that *viral load-informed differentiated care* using DBS is expected to be cost-effective and is recommended as the strategy for patient monitoring, although further empirical evidence as the approach is rolled out would be of value. We also explore the potential benefits of future availability of point-of-care (POC) viral load tests.

Introduction

It is critical for sustainability of antiretroviral therapy (ART) programmes in sub-Saharan Africa that the approach to monitoring people on therapy is optimized with regard to effectiveness and cost. Currently, in most countries patients, are required to attend clinics every 1–3 months for clinical assessment, with the costs of providing for such clinic attendances – for personnel, infrastructure and maintenance - being comparable with costs of the antiretroviral drugs themselves (1–3). In most settings, patients are monitored with CD4 count measurement every 6 months with clinical observation at least every 3 months, but are rarely switched to second-line regimens. A reduction in visit frequency in patients who are adherent to ART and doing well would benefit programmes by reducing costs and patients by saving travel costs and time away from work, possibly leading to reduced rates of defaulting from care (4). To achieve this it is necessary to be able to identify objectively who is doing well on ART.

The biomarker which most directly measures the on-going effect of ART is the HIV ribonucleic acid (RNA) level in plasma (“viral load”). If viral load is suppressed, it indicates good adherence to drug taking and lack of drug-resistant virus. Experience in high income countries suggests that after 1–2 years on ART with viral load suppression visit frequency can be reduced. If viral load is unsuppressed this suggests the need for improved adherence and/or a switch in regimen. In most countries in sub-Saharan Africa, measurement of viral load is not so far widely available. Quantification of HIV RNA requires sophisticated facilities and skilled staff and costs have been high, although they have decreased substantially recently (5, 6). While modelling studies have indicated there is a benefit of viral load monitoring over monitoring strategies based on the CD4 count or clinical observation (7–16) viral load monitoring has not been found to be cost-effective (7, 10–14),

due to the cost of viral load tests and second-line regimens. Currently, the most feasible approach in most countries to begin to measure viral load is to collect samples as dried blood spots (DBS). DBS are stable at ambient temperature and can be prepared from capillary whole blood eliminating the need for phlebotomy services (15). Using existing networks for early infant HIV diagnosis, they can be transported to a regional or national laboratory with results subsequently returned to the clinic by means such as SMS. However, presence of cells and low sample volume in DBS specimens mean that sensitivity and specificity for detecting whether the level is above the 1000 cps/mL threshold used to define viral suppression are imperfect and it is unclear if the approach is adequate (5, 16–27). Looking to the future, it is anticipated that “point-of-care” (POC) tests - i.e. tests that enables a decision to be made about patient management at the same visit as the sample is taken - may become widely available (28), and this may facilitate scale-up and result in greater accuracy than use of DBS.

In the light of these issues, we here consider the question of how should HIV treatment programmes in low- income countries in sub-Saharan Africa monitor patients on ART in a way that is likely to lead to greatest population health gains from within limited resources available (29). Here we update a model previously used to compare monitoring strategies incorporating the new lower costs and the potential for viral load-informed “differentiated care” based on reducing clinic visit costs by reducing visit frequency among virally-suppressed individuals (30, 31).

Methods

The HIV Synthesis Transmission model is an individual-based stochastic model of heterosexual transmission, natural history, clinical disease, and treatment of HIV infection incorporating use of specific drugs, resistance mutations, and adherence, which has been described previously (8,32–36).

Modelling of ART programme scenario and ART monitoring strategies

We based our simulated population around that in Zimbabwe and the the underlying model is described in detail in the Supplementary Material. We assumed that up to year 2015 a CD4 count monitoring strategy has been employed. Then we considered introduction of plausible alternative monitoring strategies and predicted outcomes over 20 years to 2035. The seven main monitoring strategies compared, which are detailed in Table 1 (together with the short-hand names we use for the strategies from now on), cluster into three main types: clinical observation (with or without targeted CD4 count or viral load testing in those with clinical disease), regular CD4 count testing, or regular viral load monitoring. In the case of viral load monitoring we simulate a strategy consisting of off-site laboratory-based testing of DBS using the World Health Organization (WHO) recommended 1000 RNA cps/mL threshold. Viral load measured < 1000 cps/mL in the past year is assumed to lead to a reduction in non-ART programme costs due to lowered frequency of clinic visits in people on first line ART. Measurement of viral load ≥ 1000 cps/mL is assumed to lead to a targeted adherence counselling intervention, which increases adherence in some people. We refer to this strategy as *viral load-informed differentiated care*. Regardless of the monitoring strategy

used, once strategy-specific failure criteria are met we assume a probability of switching to a second-line regimen of 0.5 per three months. In practice currently switch rates are lower than this, even in settings with viral load monitoring in place (37–39) but we chose this higher probability in order to be able to discern differences in effects between strategies. In sensitivity analyses we consider a situation in which switch rates are zero. Throughout, we assume monitoring is performed only for people on first-line ART.

We model decreased precision of DBS for measuring viral load by considering the presence of HIV RNA in cells and the small sample volume (5, 25, 40) such that the sensitivity and specificity of the measure for detecting viral load >1000 cps/mL compared with measurement on a plasma sample are 86% and 92%, respectively (compared with values ranging from 81%–85% sensitivity and 88%–99% specificity in (5) for most assays); we consider other values in sensitivity analysis. We also assume there is a 3 month delay in the clinician acting on the result with the patient (i.e at the next clinical visit, even though the turn-around time of getting the result back to the clinic is generally less than this).

Sensitivity analyses were performed to consider: possible differences in population adherence profile, potential future increases in sexual behaviour, changes in effectiveness of the adherence intervention triggered by viral load being > 1000 cps/mL, a policy of initiation of ART at diagnosis, that visit frequency might be reduced in those with CD4 count > 350/mm³ in the past year, a zero rate of switch to second-line, differences in the baseline prevalence of HIV, differences in the proportion on ART, differences in the rate of ART interruption if visit frequency has been reduced due to viral load being < 1000 copies/mL, a higher discount rate of 5% rather than 3%, and a 10 year time horizon instead of 20. Additionally, we considered whether whole blood or plasma is used, whether the test is done in a central laboratory and incurring the 3 month delay in acting on the result or at POC with no delay, the threshold to define failure (200, 1000 or 5000 which is only assessed in the context of plasma), and the frequency of measurement (6 monthly, annually or 2 yearly).

Lastly, we focussed on the specific comparison between viral load using DBS and using a plasma-based POC test to quantify the extent of various potential advantageous features of a POC test on its cost-effectiveness in relation to use of DBS. It is important to note that we are considering *potential* features of a POC test – it is not clear that such features can be delivered, so this analysis is directed mainly towards developers and should not be interpreted as indicating that POC tests will necessarily prove to have any of these advantageous features. This is why we chose to consider a plasma-based POC test, although in reality it may be more likely that a whole blood-based test is used in order to avoid a plasma separation step. Further details of how all these aspects are modelled are provided in the Supplementary Material.

Economic Analysis

Our objective is to maximize population health - the health benefits associated with the alternative monitoring strategies estimated using the metric disability-adjusted life years (DALYs) averted – from within available resources. A health sector perspective has therefore been adopted for the analysis. Direct and indirect costs incurred by the patients are excluded. Both costs and health benefits were discounted to present value using a 3% per

annum discount rate in our base case. The expected costs and health outcomes associated with each monitoring strategy can be compared to inform which is likely to represent best value from available resources. The cost-effectiveness threshold for a country represents the opportunity costs of resources required to fund the intervention, in terms of the health gains those resources could generate if used for alternative purposes in the public health care system (41). As such, the threshold for a country is not readily apparent, but \$500 per DALY averted is likely to be at the upper end based on the magnitude of benefit if resources were spent on other programmatic priorities such as eliminating coverage gaps for ART if these are large (42). The modelling results are intended to inform decisions in sub-Saharan African countries classified as low and low-middle income using the World Bank country classifications; which have typically struggled to scale-up viral load monitoring (31). The analyses may also be informative to higher income countries in the region (e.g. South Africa, Botswana) that have already scaled up viral load monitoring but are seeking more efficient ways to deliver ART.

Disability weights to calculate DALYs averted were derived from a recent comprehensive study (43). Unit costs (in \$US at 2014 prices) are detailed in Supplementary Material. In brief, costs of viral load assays are assumed to be \$22, counting all components of the cost (reagents, costs of equipment, human resources, buildings, etc) (details in Supplementary Material). Since POC VL tests are not yet available it was not possible to know the cost so we assumed a similar cost of \$22 although it is likely that costs will be higher than this. The cost of measuring CD4 counts is assumed to be \$10 (44). The current annual cost (including supply chain) of the first-line regimen of efavirenz, emtricitabine, tenofovir (assumed used as a fixed dose combination) is assumed to be \$144 per person per year and second-line regimen of zidovudine, emtricitabine, ritonavir-boosted atazanavir \$312 per person per year (44). Annual programme costs for clinic visits (not including drug or viral load/CD4 count tests) are \$80 per year (1,2) with an assumed reduction to \$40 per year following measurement of viral suppression because of reduced clinical visit frequency to 6-monthly from 1–3 monthly visits (with interim pharmacy-only visits depending on amount of drug that can be dispensed).

Results

The status of the simulated population in 2014 is shown in Supplementary Material (Table S1). Mean predicted outcomes over 20 years are shown in Table 2. The proportion of ART-experienced people who have fulfilled the criteria for failure of first-line ART is lowest with no monitoring and is below 15% for each of the clinical monitoring strategies. It is highest for the *CD4 count monitoring (WHO)* strategy (41%) because the failure definition is fulfilled if the CD4 count is below pre-ART baseline level (which can occur due to high CD4 count variability, and particularly if ART has been interrupted for a period). The proportion is intermediate for the *CD4 count monitoring (< 200)* strategy and *viral load-informed differentiated care using DBS* strategies (at 24% and 25%, respectively). The proportion of all people on ART who have viral suppression is highest with the *viral load-informed differentiated care using DBS* strategy (86%) and lowest with *no monitoring* (76%), with the small range of 10% reflecting the generally high levels of adherence (although we consider in sensitivity analyses a situation in which adherence levels are lower

and the proportion with viral suppression is accordingly lower). The death rate is markedly lower for the CD4 count and viral load monitoring strategies than for the other strategies, and this is particularly evident in those among whom viral load failure has occurred. Notably, there is also a benefit of *viral load-informed differentiated care using DBS* on HIV incidence over all the other strategies.

Costs and their components by monitoring strategy are given in Figure 1. Programme costs for clinic visits are lowest with *viral load-informed differentiated care using DBS* due to the reduction in clinic visit frequency among virally suppressed persons. Figure 2 shows the cost effectiveness plane, indicating the total DALYs averted in the population over 20 years together with the increment in costs (both discounted), compared with *no monitoring*. Due to the higher death rate in people on ART and higher incidence, the clinical monitoring strategies avert less DALYs than the viral load and CD4 count-based monitoring strategies. Additional costs incurred are greatest for CD4 count monitoring. *Viral load-informed differentiated care using DBS* averts a similar number of DALYs as CD4 count monitoring and is the most cost effective strategy due to the reduction in non-ART programme costs in people with viral suppression, with an incremental cost effectiveness ratio (ICER) of \$326 per DALY averted. Figure 3 depicts how the ICER is affected by the assumed costs of viral load tests and savings in clinic visit costs in people with suppressed viral load. At our base case viral load test cost of \$22, viral load-informed differentiated care is cost-effective only so long as reduced clinic visits provide at least a \$30 per person per year saving offset.

In Figure 4 and Supplementary Figure 1, we consider the effect of varying model assumptions. Changes in the sensitivity and specificity of viral load measurement using whole blood (as used for DBS) did not markedly influence the ICER, nor did the extent of the assumed effect of viral load measurement > 1000 cps/mL on adherence. The ICER for viral load-informed differentiated care was lower when we assumed lower population adherence and when we assumed higher population levels of condomless sex, resulting in higher HIV incidence. In a scenario with a switch rate of zero, viral load informed differentiated care was cost saving. Confirming the results in Figure 3, if no reduction in visit frequency is assumed with viral load monitoring (Supplementary Figure 1(u)) then it is not cost-effective. The only other scenarios in which viral load-informed differentiated care was not cost effective was when we considered a 10 year time horizon instead of 20 years and when we considered a doubling of rate of ART interruption in people with a reduced visit frequency due to viral load being < 1000 copies/mL (Figure 4 and Supplementary Figure 1(q and r)).

In the base case we have considered there to be a switch rate of 0.5 per 3 months after the strategy-specific failure criteria have been met. In practice, currently in most settings, despite CD4 counts being measured, switching rates are much lower than this. In Figure 5 we compared use of the *CD4 count monitoring (WHO)* strategy with a low switch rate of 0.05 per 3 months (the current situation in many countries) - with viral load-informed differentiated care with a switch rate of 0.5 per 3 months. This suggests that introduction of the *viral load-informed differentiated care using DBS* accompanied by a high switch rate would lead to a substantial improvement in DALYs averted with a potential *reduction* in cost, compared with the current situation. In the simulated model population of Zimbabwe,

over 20 years the *CD4 count monitoring (WHO)* strategy averts 0.54m DALYs compared to *no monitoring* at a cost of \$500m whereas *viral-load informed differentiated care using DBS* averts 1.12m DALYs compared to no monitoring at a cost of \$361m.

In Figure 6 we consider only the viral load-informed differentiated care strategy and assess the effect of variations in various aspects; whether whole blood or plasma is used, whether the test is POC (central laboratory testing using whole blood is our DBS scenario), the threshold to define failure (200, 1000 or 5000, which is only assessed in the context of plasma), and the frequency of measurement (6 monthly, annually or 2 yearly). Monitoring 6-monthly instead of annually averts more DALYs but does not appear cost effective at the \$500 threshold (ICER=\$1,234). Less frequent monitoring (e.g. every 2 years) would be cost-effective if it were to avert a similar number of DALYs to monitoring every year. However, implementing differentiated care based on viral load monitoring as infrequently as every 2 yearly is currently untested and potential downside health consequences are unknown so this strategy is excluded from the comparison (i.e. it is crossed out in Figure 6a). Using the 5000 cps/mL threshold also averts DALYs at a similar ICER to the 1000 cps/mL threshold, but with reduced total benefit. Use of a whole blood sample (e.g. DBS) instead of a plasma sample is not predicted to result in a marked difference in cost incurred (assuming the same unit cost per test) and a modest (4%) benefit in DALYs averted. There is a modest (6%) benefit of POC over laboratory monitoring in DALYs averted due to the fact that the 3 months delay is avoided.

Discussion

Our results suggest that viral load-informed differentiated ART care, using DBS sampling if necessary, is likely to be cost effective in low-income settings in sub-Saharan Africa and represents a sustainable model for providing ART. That said, the level of savings resulting from reduced clinic visits that can be realized in practice with differentiated care are as yet not certain and require monitoring. The extent of savings depends partially on the cost of viral load testing: with the fully-loaded viral load test cost of \$22 used in our base case an annual saving of at least \$30 per year in those with viral suppression is required for viral load-informed differentiated ART care to be cost-effective. Given annual non-ART programme costs averaging around \$80 per year (2) in the context of patients being seen 1–3 monthly, reduction in visit frequency to 6 monthly, and perhaps in time for long term suppressed patients to 9–12 monthly, should enable such savings. There is little evidence that patients seen at sites with higher non-ART programme costs have better outcomes (2). We estimate based upon modelling Zimbabwe over 20 years, that in contrast to the current situation in many countries of CD4 count monitoring with low switch rates, introduction of viral load-informed differentiated care would more than double the number of DALYs-averted compared to no monitoring (1.12m vs 0.54m) and deliver these at reduced costs (\$360m vs \$500m).

Reduction in clinic visit frequency could also affect patients' adherence to ART and retention in care. There is some evidence that a reason for patients' defaulting from care is due to an inability to keep up with the intensive clinic visit schedule due to travel time and cost and loss of work time (4). Notably, retention in care was over 90% at four years among

individuals enrolled in community ART clubs in Mozambique, due in part to community-based adherence support, decreased travel requirements, and patient preference (46,47). We did not include in our model any such adherence or retention benefits associated with differentiated care. There is also the possibility patients may feel less connected to care with a differentiated care model, with adverse consequences for adherence and retention.

When using the CD4 count to monitor people on ART, the WHO recommended approach has been to define failure by a CD4 count $< 100/\text{mm}^3$ or a decline from pre-ART baseline. Our modelling suggests that, given the high variability in CD4 count and the fact that it is not infrequent for people to interrupt ART for periods of time, this latter component results in low specificity and many patients with viral suppression would be incorrectly categorized as failing and hence switched unnecessarily. The alternative approach we evaluated, similar to that used in the DART trial (48), is to define failure based on a CD4 < 100 in years 1–3 on ART, and a CD4 count < 200 thereafter. This approach performed well in our modelling in terms of the death rate in people on ART (as it did in the trial itself), although it still resulted in a lower rate of viral suppression and hence a higher HIV incidence than with viral load monitoring, resulting in overall poorer effectiveness. In settings which continue to have CD4 count capacity but not viral load capacity, this suggests the *CD4 count monitoring (<200)* strategy should be used, until viral load-informed differentiated care is introduced.

The requirement for frequent clinic visits is partially driven by shortages of ART supplies at the national level, resulting in clinic level rationing of ART quantities dispensed to patients at each visit. Increasing country buffer stocks, as well as improving forecasting of need, could enable longer drug supplies to be prescribed. However, even if it remains not possible to prescribe more than 1–2 months of drug, various approaches can be considered to prevent patients having to make frequent pharmacy-only visits to clinic (46,47,49–54). These include community ART groups, whereby one member picks up drug for all the members, or patients are allowed to pick up medicines in a shop or other non-clinical setting (55). Other hurdles to overcome in adopting viral load-driven reductions in frequency of clinical visits include obtaining buy-in from Ministries of Health for any required task shifting, and provision of human resources for dedicated adherence support for people with high viral load. In addition, support from professional associations of clinical, nursing and pharmacy staff will be important.

The fact that the viral load is a direct measure of the on-going effect of treatment means it provides an ideal means to differentiate care provision. However, given current wider availability of CD4 count tests, it might be suggested that the CD4 count could be used instead. It might be, for example, that visit frequency for people with a CD4 count above $350/\text{mm}^3$ could be reduced. This would result in a similar reduction in clinic visit costs to viral load informed differentiated care. The effectiveness of such an approach is unknown, however. It would lead to some people in whom adherence is low and/or resistance is present and viral load is high being asked to visit clinic less frequently. It is well established that CD4 counts can remain high when virologic failure is occurring (56) and, likewise, that the CD4 count can remain low despite full virologic suppression. Thus, there would be concern over the negative effects of such a strategy and, while we did model this as a potential

strategy (Supplementary Figure 1(j)) it is possible that we did not fully capture the extent of those negative effects.

We have largely focussed on use of DBS rather than plasma collection as an approach. While plasma samples from a venepuncture and sample separation represent an ideal sample, for transport over 6–24 hours this requires cold temperature and so the approach is only likely to be applicable in areas for which samples can reach the laboratory in that time.

While we have argued that a DBS approach is feasible in most settings, this is not to say that the approach is working well everywhere (57). It is important that there is investment in improvements to existing systems, including diagnostics laboratories and logistics of specimen distribution, and we have endeavoured to capture these costs as part of our overall costs of delivering viral load testing using DBS. It is notable that most studies evaluating viral load using DBS compared to plasma have been performed in a laboratory setting using venipuncture samples and a capillary tube to fill in the DBS card. Few studies are available to assess performance of DBS in the real world scenario where it is hot, sample transport times are long, where venipuncture is not an option, and where samples are from a finger prick rather than a capillary tube in order to measure a precise 100 μ l whole blood amount per DBS, although one such study has found encouraging findings (27). Our finding of cost effectiveness of viral load informed differentiated care was robust to low levels of sensitivity or specificity using DBS (Figure 4 and Supplementary Figure 1).

We simplified consideration of types of viral load test by breaking them down according to whether done at POC or in a laboratory and whether the sample consisted of whole blood or plasma. We recognise that this is something of an over-simplification in that, for example, measurement of viral load by POC testing on whole blood may not always have the same sensitivity/specificity as using whole blood in the form of DBS. Improved sensitivity and specificity compared with DBS offers a modest but real benefit, as does the ability to measure the viral load level such that it can be acted on the same day, avoiding a delay until the next visit or the need to contact and recall the patient. Even if a POC viral load test with the desirable properties we considered does become available it is likely that countries would use a mix of approaches, with plasma samples, DBS and POC, depending on settings. It should be noted that that cost we assumed for a POC assay of \$22 was essentially used as a place-holder for the actual cost when this becomes known. It is uncertain whether such tests will be able to be delivered at this as a fully-loaded cost which takes account of staff operator time, and our results should be interpreted in the light of this.

If differentiated care can be implemented using viral load monitoring less frequently than every 12 months (e.g. every 24 months), our modelling suggests that less frequent monitoring would be expected to be cost-effective. However, the health risks of differentiated care with infrequent viral load monitoring are not well understood and may not have been fully captured in our model. Further evidence on whether this approach is feasible, and the health consequences of its implementation, is required. Only in highly resourced healthcare systems (with a cost-effectiveness threshold above \$1400 per DALY averted) is more frequent monitoring (e.g. every 6 months) expected to be cost-effective.

We found little evidence of substantial benefits associated with moving from a cut-off to define treatment failure of viral load counts > 1000 cps/mL towards either a lower or a higher cut-off. A cut-off of 200 results in more DALYs being averted – due to identifying people with virologic failure earlier - but relies on a plasma-based test (and phlebotomy to achieve sufficient sample volume) and is not cost-effective at the \$500 cost-effectiveness threshold.

Given the role of viral load testing for enabling reduced visit frequency it should have a role also in people on second-line regimens. When evaluating our monitoring strategies we assumed that CD4 count/viral load tests would only be done in patients on first-line, so we may have understated the benefits of viral load-informed differentiated care.

We considered whether our base case results would still hold with various alterations in assumptions and settings. In a scenario in which the pattern of adherence was generally poorer than in our base case (leading to 68% of people on ART with viral suppression compared with 82%) viral load-informed differentiated care remained cost-effective. Likewise in a scenario with high incidence rate, and scenarios with different HIV prevalence and ART coverage, suggesting our findings should hold quite broadly in various settings in the region.

Randomized trials have been performed to compare outcomes from CD4 count and viral load monitoring and these have not identified significant differences in outcome. Such trials have been characterised by relatively short follow-up and low implementation of switching to second-line therapy (58–64) leading to low power to detect differences.

We focussed on monitoring for adults. In children and, more likely, adolescents levels of adherence may be lower than in adults. We did find that our main findings hold in populations with tendency for lesser adherence. However, there may be greater reluctance to reduce visit frequency as children are growing up and constantly facing new challenges and situations. Likewise, in women in the year or so post-partum there may be reluctance to reduce visit frequency. We also considered whether 6-monthly monitoring would be cost-effective for populations with poorer adherence profile (Supplementary Figure 1t) but this was not the case. Other limitations of this work include the fact that we considered a hypothetical cohort with simulated outcomes, and future trends are uncertain, particularly in sexual behaviour, levels of male circumcision and adherence to ART. Further, we assume continuation of HIV testing and ART availability at current trends. The profile of new POC VL tests is also as yet uncertain as is their cost. However, new diagnostic technologies, including POC viral load testing and beyond, have great potential to enhance delivery of HIV care. We have investigated uncertainty through a series of one-way and multi-way sensitivity analyses and recognize there are other approaches such as probabilistic sensitivity analysis and approximate Bayesian computation that we intend to pursue in further work.

This work provides insights into how to deliver ART monitoring so that it is both effective and cost-effective. As well as providing some specific guidance to programmes it highlights the need to research this area further, to enable us to continue to understand the attributes of programmes and to determine how maximum health gains can be realized by patients from

within the constrained resources available. We find that evidence is sufficient to recommend viral-load differentiated care using DBS but that further empirical confirmation as the approach is rolled out would be valuable.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding for the study was received from the HIV Modelling Consortium, the Bill and Melinda Gates Foundation, the World Health Organization and the HIV Diagnostics Modelling Consortium. We are grateful for the use of cluster computing facilities at UCL - Legion@UCL - without which this work would not have been possible. Dr Lundgren is supported by the Danish National Research Foundation (DNRF:126).

Funding: Bill & Melinda Gates Foundation (specific diagnostics grant and HIV Modelling Consortium).

Appendix: Working Group on Cost effectiveness of ART Monitoring Strategies in Sub-Saharan Africa

Andrew Phillips, UCL, Amir Shroufi, MSF, Lara Vojnov, CHAI, Jennifer Cohn, MSF, Teri Roberts, MSF, Tom Ellman, MSF, Kimberly Bonner, MSF, Christine Rousseau, BMGF, Geoff Garnett, BMGF, Valentina Cambiano, UCL, Fumiyo Nakagawa, UCL, Deborah Ford, UCL, Loveleen Bansi-Matharu, UCL, Alec Miners, LSHTM, Jens Lundgren, Rigshospitalet, Copenhagen, Denmark, Jeff Eaton, Imperial, Rosalind Parkes-Rotanshi, IDI Uganda, Zachary Katz, CHAI, David Maman, MSF, Nathan Ford, WHO, Marco Vitoria, WHO, Meg Doherty, WHO, David Dowdy, Brooke Nichols, Maurine Murtagh, Meghan Wareham, Kara Palamountain, Christine Chiedza Musanhu, Wendy Stevens, David Katzenstein, Andrea Ciaranello, Ruanne Barnabas, Scott Braithwaite, Eran Bendavid, Kusum J Nathoo, David van de Vijver, David Wilson, Charles Holmes, Anna Bershteyn, Simon Walker, University of York, Elliot Raizes, Ilesh Jani, Lisa Nelson, Rosanna Peeling, Fern Terris-Prestholt, Joseph Murungu MoHCC Zimbabwe, Tsitsi Mutasa-Apollo MoHCC Zimbabwe, Tim Hallett, Imperial College, Paul Revill, U of York.

References

1. Siapka M, Remme M, Dayo Obure C, Maier C, Dehne KL, Vassall A. Is there scope for cost savings and efficiency gains in HIV services? A systematic review of the evidence from low- and middle-income countries. *Bull World Health Organ.* 2014; 92:499–511AD. doi: <http://dx.doi.org/10.2471/BLT.13.127639>. [PubMed: 25110375]
2. Tagar E, Sundaram M, Condliffe K, Matatiyo B, Chimbwandira F, et al. Multi-Country Analysis of Treatment Costs for HIV/AIDS (MATCH): Facility-Level ART Unit Cost Analysis in Ethiopia, Malawi, Rwanda, South Africa and Zambia. *PLoS ONE.* 2014; 9(11):e108304. doi: 10.1371/journal.pone.0108304 [PubMed: 25389777]
3. Menzies NA, Berrutia AA, Berzon A, Filler S, Ferris R, Ellerbrock TV, et al. The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. *AIDS.* 2011; 25:1753–1760. [PubMed: 21412127]
4. Ware NC, Wyatt MA, Geng EH, Kaaya SF, Agbaji OO, et al. Toward an Understanding of Disengagement from HIV Treatment and Care in Sub-Saharan Africa: A Qualitative Study. *PLoS Med.* 2013; 10(1):e1001369. doi: 10.1371/journal.pmed.1001369 [PubMed: 23341753]

5. World Health Organisation. Technical and operational considerations for implementing HIV viral load testing. Access to HIV diagnostics. Jul. 2014 www.who.int
6. UNAIDS. Landmark HIV diagnostic access program will save \$150m and help achieve new global goals on HIV. <http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2014/september/20140925prviralload>
7. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. *Lancet*. 2008; 371:1443–51. [PubMed: 18440426]
8. Estill J, Aubriere C, Egger M, et al. Viral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa: a mathematical modelling analysis. *AIDS*. 2012; 26:1403–13. 2012. [PubMed: 22421243]
9. Braithwaite RS, Nucifora KA, Yiannoutsos CT, et al. Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives? *J Intl AIDS Soc*. 2011; 14:38.
10. Kimmel AD, Weinstein MC, Anglaret X, et al. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. *J Acquir Immune Defic Syndr*. 2010; 54:258–68. [PubMed: 20404739]
11. Braithwaite RS, Nucifora KA, Toohey C, et al. How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa? *AIDS*. 2013
12. Estill J, Egger M, Johnson LF, et al. Monitoring of antiretroviral therapy programmes in Malawi, South Africa and Zambia: Mathematical Modelling Study. *PLoS One*. 2013; 8:e57611.15. [PubMed: 23469035]
13. Keebler, D.; Revill, P.; Braithwaite, S.; Phillips, AN.; Blaser, N.; Borquez, A.; Cambiano, V., et al. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models. *Lancet Glob Health*. 2013. [http://dx.doi.org/10.1016/S2214-109X\(13\)70048-2](http://dx.doi.org/10.1016/S2214-109X(13)70048-2)
14. Bendavid E, et al. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. *Archives of Internal Medicine*. 2008; 168(17)
15. Hamers RL, Sawyer AW, Tuohy M, Stevens WS, Rinke de Wit TF, Hill AM. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis. *AIDS*. 2012; 26:1663–72. [PubMed: 22695297]
16. Rutstein SE, Hosseinipour MC, Kamwendo D, Soko A, Mkandawire M, Biddle AK, et al. Dried Blood Spots for Viral Load Monitoring in Malawi: Feasible and Effective. *PLoS ONE*. 2015; 10(4):e0124748.doi: 10.1371/journal.pone.0124748 [PubMed: 25898365]
17. Andreotti M, et al. Correlation between HIV-1 viral load quantification in plasma, dried blood spots, and dried plasma spots using the Roche COBAS Taqman assay. *J Clin Virol*. 2010; 47:4–7. [PubMed: 19962936]
18. Garrido C, Zahonero N, Corral A, et al. Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests. *J Clin Microbiol*. 2009; 47:1031–6. [PubMed: 19193847]
19. Johannessen A, et al. Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania. *Clin Infect Dis*. 2009; 49:976–81. [PubMed: 19663598]
20. Marconi A, et al. Evaluation of the Abbott Real-Time HIV-1 quantitative assay with dried blood spot specimens. *Clin Microbiol Infect*. 2009; 15:93–7. [PubMed: 19220340]
21. Arredondo M, et al. Comparison of HIV-1 RNA measurements using plasma and dried blood spots (DBS) in the Automated Abbott Real Time Viral Load Assay. *J Clin Microbiol*. 2011 (published ahead of printing).
22. Pirillo MF-Pinson P, et al. Quantification of HIV-RNA from dried blood spots using Siemens VERSANT® HIV-1 RNA (kPCR) assay. *J Antimicrob Chemother*. 2011; 66:2823–6. [PubMed: 21930572]

23. Ondo, P.; Shamu, T.; Bronze, M.; Wellington, M.; Sonia Boender, T.; Manting, C., et al. Performance and Logistical Challenges of Alternative HIV-1 Virological Monitoring Options in a Clinical Setting of Harare, Zimbabwe. *BioMed Research International* Volume. 2014. <http://dx.doi.org/10.1155/2014/102598>
24. Fajardo E, Metcalf C, Chaillet P, Aleixo L, Pannus P, Panunzi I, et al. Prospective Evaluation of Diagnostic Accuracy of Dried Blood Spots from Finger Prick Samples for Determination of HIV-1 Load with the NucliSENS Easy-Q HIV-1 Version 2.0 Assay in Malawi.
25. Smit PW, Sollis KA, Fiscus S, Ford N, Vitoria M, et al. Systematic Review of the Use of Dried Blood Spots for Monitoring HIV Viral Load and for Early Infant Diagnosis. *PLoS ONE*. 2014; 9(3):e86461.doi: 10.1371/journal.pone.0086461 [PubMed: 24603442]
26. Rutstein E, Kamwendo Lugalid L, Thengolose I, Tegha G, Fiscus AS, et al. Measures of viral load using Abbott RealTime HIV-1 Assay on venous and fingerstick dried blood spots from provider-collected specimens in Malawian District Hospitals. *Journal of Clinical Virology*. 2014; 60:392–398. [PubMed: 24906641]
27. Mavedzenge SN, Davey C, Chirenje T, Mushati P, Mtetwa S, Dirawo J, et al. Finger Prick Dried Blood Spots for HIV Viral Load Measurement in Field Conditions in Zimbabwe. *PloS ONE*. 2015; 10(5):e0126878.doi: 10.1371/journal.pone.0126878 [PubMed: 26001044]
28. UNITAID. HIV/AIDS Diagnostics Technology Landscape. Semi annual update. 2015. www.unitaid.org
29. http://data.worldbank.org/about/country-and-lending-groups#Sub_Saharan_Africa
30. Duncombe C, Rosenblum S, Hellmann N, Holmes C, Wilkinson L, Biot M, et al. Reframing HIV care: putting people at the centre of antiretroviral delivery. *Tropical Medicine and International Health*. 2015; 20:430–447. DOI: 10.1111/tmi.12460 [PubMed: 25583302]
31. Roberts T, Bygrave H, Fajardo E, Ford N. Challenges and opportunities for the implementation of virological testing in resource-limited settings. *J Int AIDS Soc*. 2012; 15:17324. <http://www.jiasociety.org/index.php/jias/article/view/17324><http://dx.doi.org/10.7448/IAS.15.2.17324>. [PubMed: 23078767]
32. Cambiano V, Bertagnolio, Jordan M, et al. Transmission of Drug Resistant HIV and Its Potential Impact on Mortality and Treatment Outcomes in Resource-Limited Settings. *J Infect Dis*. 2013; 207:S57–62. [PubMed: 23687290]
33. Cambiano V, Bertagnolio S, Jordan M, Pillay D, Perriens J, Venter F, et al. Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation. *AIDS*. 2014; 28(Suppl 1):S15–S23. [PubMed: 24468943]
34. Phillips, AN.; Cambiano, V.; Miners, A.; Revill, P.; Pillay, D.; Lundgren, JD., et al. Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naïve populations beginning treatment: modelling study and economic analysis. *Lancet HIV*. Oct 14. 2014 [http://dx.doi.org/10.1016/S2352-3018\(14\)70021-9](http://dx.doi.org/10.1016/S2352-3018(14)70021-9)
35. Cambiano V, Ford D, Mabugu T, et al. Assessment of the potential impact and cost-effectiveness of self-testing for HIV in low-income countries. *J Infect Dis*. 2015
36. Phillips AN, Pillay D, Garnett G, et al. Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line regimens in resource-limited settings. *AIDS*. 2011; 25:843–50. [PubMed: 21192233]
37. Madec Y, Leroy S, Rey-Cuille M-A, Huber F, Calmy A. Persistent Difficulties in Switching to Second-Line ART in Sub-Saharan Africa — A Systematic Review and Meta-Analysis. *PLoS ONE*. 2013; 8(12):e82724.doi: 10.1371/journal.pone.0082724 [PubMed: 24376570]
38. Fox MP, Cutsem GV, Giddy J, Maskew M, Keiser O, Prozesky H, et al. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. *J Acquir Immune Defic Syndr*. 2012 Aug 1; 60(4):428–37. [PubMed: 22433846]
39. Johnston V, Fielding KL, Charalambous S, Churchyard G, Phillips A, Grant AD. Outcomes following virological failure and predictors of switching to second-line antiretroviral therapy in a South African treatment program. *J Acquir Immune Defic Syndr*. 2012 Nov 1; 61(3):370–80. [PubMed: 22820803]

40. Parkin N. Measurement of HIV-1 viral load for drug resistance surveillance using dried blood spots: literature review and modelling of contribution of DNA and RNA. *AIDS Reviews*. 2014; 16:160–171. http://www.aidsreviews.com/files/2014_16_3_160-171.pdf. [PubMed: 25221990]
41. Claxton, K.; Walker, S.; Palmer, S.; Sculpher, M. Centre for Health Economics Research Paper 54. University of York; 2010. *Appropriate Perspectives for Health Care Decisions*.
42. Woods, E.; Revill, P.; Sculpher, M.; Claxton, K. Country-Level Cost- Effectiveness Thresholds: Initial Estimates and the Need for Further Research. https://www.york.ac.uk/media/che/documents/papers/researchpapers/CHERP109_cost-effectiveness_threshold_LMICs.pdf
43. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. *Lancet*. 2012; 380:2129–4310. [PubMed: 23245605]
44. Hyle EP, Jani IV, Lehe J, Su AE, Wood R, Quevedo J, et al. The Clinical and Economic Impact of Point-of-Care CD4 Testing in Mozambique and Other Resource-Limited Settings: A Cost-Effectiveness Analysis. *PLoS Med*. 2014; 11(9):e1001725.doi: 10.1371/journal.pmed.1001725 [PubMed: 25225800]
45. MSF. Untangling the web of antiretroviral price reductions. 17thJul. 2014 www.msfastcess.org
46. Decroo T, Koole O, Remartinez D, dos Santos N, Dezembro S, Jofrisse M, et al. Four-year retention and risk factors for attrition among members of community ART groups in Tete, Mozambique. *Trop med and Int Health*. 2014; 19:514–521. [PubMed: 24898272]
47. Rasschaert F, Decroo T, Remartinez D, Telfer B, Lessitala F, Biot M, et al. Sustainability of a community-based anti-retroviral care delivery model - a qualitative research study in Tete, Mozambique.
48. DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. *Lancet*. 2010 Jan 9; 375(9709):123–131. DOI: 10.1016/S0140-6736(09)62067-5 [PubMed: 20004464]
49. MSF. ART adherence club report and toolkit. http://www.msf.org/sites/msf.org/files/cag_toolkit.pdf
50. MSF. Community ART Group Toolkit. How to implement the CAG model. Bringing treatment closer to home and empowering patients. <http://samumsf.org/resources/toolkit-cag/>
51. Simons, S.; et al. MSF. Consultation on Implementation Issues for Monitoring People on ART in Low-Income Settings in Sub-Saharan Africa. Harare, Zimbabwe: Mar 11–12. 2015 *Ways to reduce costs and improve quality in patient monitoring: barriers to improvement, Buhera & Gutu district experience, Zimbabwe*.
52. Babigumira JB, Castelnuovo B, Stergachis A, Kiragga A, Shaefer P, et al. Cost-effectiveness of a Pharmacy-Only Refill Program in a Large Urban HIV/AIDS Clinic in Uganda. *PLoS ONE*. 2011; 6(3):e18193.doi: 10.1371/journal.pone.0018193 [PubMed: 21464895]
53. UNAIDS and Medecins Sans Frontieres. Community based ART delivery. Experiences of MSF.
54. Grimsrud A, et al. Implementation of community-based adherence clubs for stable antiretroviral therapy patients in Cape Town, South Africa. *Journal of the International AIDS Society*. 2015; 18:19984. www.jiasociety.org/index.php/jias/article/view/19984 | <http://dx.doi.org/10.7448/IAS.18.1.19984>. [PubMed: 26022654]
55. MSF. Closer to home. www.msfastcess.org
56. Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. *Lancet*. 2004; 364:51–62. [PubMed: 15234856]
57. Terris-Prestholt F. First-line antiretroviral therapy for HIV-infected children. *AIDS*. 2015
58. Mermin J, Ekwaru JP, Were W, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial. *BMJ*. 2011; 343:d6792. [PubMed: 22074711]
59. Kahn JG, Marseille E, Moore D, et al. CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study. *BMJ*. 2011; 343:d6884. [PubMed: 22074713]

60. DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. *Lancet*. 2010; 375:123–31. [PubMed: 20004464]
61. Jourdain G, Le Coeur S, Ngo-Giang-Huong N, Traisathit P, Cressey TR, et al. Switching HIV Treatment in Adults Based on CD4 Count Versus Viral Load Monitoring: A Randomized, Non-Inferiority Trial in Thailand. *PLoS Med*. 2013; 10(8):e1001494. doi: 10.1371/journal.pmed.1001494 [PubMed: 23940461]
62. Saag, M.; Westfall, A.; Luhanga, D., et al. Cluster randomized trial of routine vs discretionary viral load monitoring among adults starting ART: Zambia; 19th Conference on Retroviruses and Opportunistic Infections; Seattle, WA, USA. March 5–8, 2012;
63. Laurent C, Kouanfack C, Laborde-Balen G, et al. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. *Lancet Infect Dis*. 2011; 11:825–33. [PubMed: 21831714]
64. Boyer S, March L, Kouanfack C, et al. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis. *Lancet Infect Dis*. 2013; 13:577–86. [PubMed: 23602084]




Figure 1. Overall programme costs in (\$m per 3 months) according to monitoring strategy (mean over 2015–2034, discounted at 3% per annum from 2015)




Figure 2. Cost effectiveness plane showing clinical- and CD4-based monitoring strategies along with viral load-informed differentiated care using DBS. ICER - incremental cost-effectiveness ratio




Figure 3. Indication of whether viral load-informed differentiated care is the most cost effective monitoring strategy according to (i) cost of viral load tests and (ii) reduction in non-ART programme costs in people with viral suppression. In context of cost-effectiveness threshold \$500. Colours indicate which monitoring strategy is economically preferred.

- (a) DBS sensitivity 96% and specificity 79% for 1000 copies/mL threshold (vs plasma)
- (b) DBS sensitivity 71% and specificity 97% for 1000 copies/mL threshold (vs plasma)
- (c) DBS sensitivity 88% and specificity 93% for 1000 copies/mL threshold (vs plasma)
- (d) DBS sensitivity 85% and specificity 79% for 1000 copies/mL threshold (vs plasma)
- (e) Poorer population ART adherence profile**
- (f) Future greater increase in sexual behaviour in population***
- (g) Permanent increase in adherence as a result of viral load measurement alert in none rather than 40%
- (h) Permanent increase in adherence as a result of viral load measurement alert in 100% rather than 40%
- (i) Policy of initiation of ART at diagnosis
- (j) Reduced frequency of visits if CD4 count measured > 350 in past year
- (k) In context of a switch rate of 0 (so only benefit of monitoring is to inform who should be seen less frequently)
- (l) In context of lower prevalence of HIV in 2014 (6% instead of 15% in base case)
- (m) In context of higher prevalence of HIV in 2015 (33% instead of 15% in base case)
- (n) In context of lower proportion on ART in 2015 (33% instead of 56% in base case)
- (o) In context of higher proportion on ART in 2015 (70% instead of 56% in base case)
- (p) 5% discount rate instead of 3%
- (q) 10 year time horizon instead of 20 year
- (r) 2 times higher rate of ART interruption if visit frequency has been reduced due to viral load being < 1000 copies/mL
- (s) 2 times lower rate of ART interruption if visit frequency has been reduced due to viral load being < 1000 copies/mL




Figure 4. Incremental cost-effectiveness ratio (ICER) for viral-load-informed differentiated care using dried blood spot (DBS) (compared with next less effective strategy on the efficiency frontier) according to changes in assumptions.

Increment in total cost over 20 years (\$m)




Figure 5. Cost effectiveness plane showing the current situation - CD4 count (WHO) monitoring with a low rate of switching in those meeting the failure criteria (0.05 per 3 months) - and viral load informed differentiated care with switch rate as in our base case (0.5 per 3 months)

Increment in total cost over 20 years (\$m)

Frequency of testing 12 monthly, vs 6monthly and 2 yearly

In context of viral load measurement using lab - whole blood (DBS) and 1000 cps/mL threshold




Figure 6a

Increment in total cost over 20 years (\$m)

Laboratory testing (3 month delay) vs POC
Whole blood vs plasma sample

In context of 12 monthly viral load measurement
and 1000 cpy/mL threshold




Figure 6b

Increment in total cost over 20 years (\$m)

Viral load threshold for switching: 1000, 200 and 5000 cps/mL

In context of 12 monthly viral load measurement using lab - plasma




Figure 6c

Figure 6.

Cost-effectiveness planes showing the effect of viral load measurement frequency, format and threshold, all in the context of viral-load-informed differentiated care. a, Viral load monitoring every 12-months is compared with every 6 months (every 2-year monitoring is excluded from the cost-effectiveness frontier due to unproven ability to base differentiated care on a 2-yearly value; however, if less frequent monitoring could be implemented without adverse health outcomes this would be cost-effective).

b, Laboratory whole blood corresponds to dried blood spot (DBS).

c, Alternative thresholds to define failure (viral load >200, >1,000 and >5,000 cps ml⁻¹) are compared in the context of laboratory monitoring every 12 months using plasma.

Table 1

Description of the seven main monitoring strategies modelled. The column heading is the short name given to the strategy.

	No monitoring	Clinical monitoring	Clinical monitoring VL confirmation	Clinical monitoring CD4 count confirmation	CD4 count monitoring (WHO)	CD4 count monitoring (<200)	Viral load-informed differentiated care, using DBS
What the monitoring strategy entails (for people on first-line ART)	-	Check on presence of symptoms every 3m.	Check on presence of symptoms every 3m. Measure viral load if WHO 4 condition diagnosed or 2 WHO 3 conditions diagnosed in 1 year.	Check on presence of symptoms every 3m. Measure CD4 count if WHO 4 condition diagnosed or 2 WHO 3 conditions diagnosed in 1 year.	6 m CD4 count. If failure criteria appear to be met, re-measure to confirm (confirmatory CD4 count).	12 m CD4 count. If failure criteria appear to be met, re-measure to confirm (confirmatory CD4 count).	VL measure using DBS at 6m, 12m and every 12m thereafter. If VL > 1000 then give adherence intervention and re-measure VL. 3 m later (confirmatory VL measure). No CD4 count measurements.
Failure criteria	-	WHO 4 condition diagnosed or 2 WHO 3 conditions diagnosed in 1 year.	VL > 1000 cps/mL	CD4 count <250/mm ³ .	CD4 count < pre-ART baseline or CD4 count < 100/mm ³ in confirmatory CD4 count	CD4 count < 200 after > 3 years on ART. CD4 < 100/mm ³ after > 1 year on ART in confirmatory CD4 count)	VL > 1000 cps/mL in confirmatory VL measure.
Reduction in clinical visit frequency (and hence reduction in non-ART programme cost) *	No	No	No	No	No	No	Yes, when most recent viral load < 1000 cps/mL, measured in past year.

* We assume 3 monthly clinical visits for all strategies except under viral load-informed differentiated care when most recent viral load < 1000 cps/mL, measured in past year. More frequent clinical visits than 3 monthly are not modelled as the model advances in 3 month periods; cps = copies; VL = viral load; WHO 4 = WHO stage 4 condition; ART = antiretroviral therapy; 3m = 3 monthly, etc.

Table 2

Outcomes over 20 years 2015–2035 in people with HIV (age 15–65) according to monitoring strategy. For each model run for each strategy, the outcome of interest (as listed in the first column) is output for each 3 month period between 2015–2035. Over 500 model runs are done for each strategy, then means are taken over 3 month periods and model runs.

	No monitoring	Clinical monitoring	Clinical monitoring VL confirmation	Clinical monitoring CD4 count confirmation	CD4 count monitoring (WHO)	CD4 count monitoring (< 200)	Viral load-informed differentiated care using DBS
Percent of ART experienced people who have fulfilled criterion for failure of first-line ART	7%	14%	10%	13%	41%	26%	27%
Percent of ART-experienced people who have started second-line ART	3%	13%	10%	13%	38%	24%	25%
Percent of people on ART who have (true) viral load < 1000 cps/mL (mean; over 20 year time horizon)	76%	79%	78%	79%	85%	82%	86%
Death rate (per 100 person years) amongst people on ART	4.43	3.63	4.06	3.67	3.02	3.07	3.18
Death rate (per 100 person-years) amongst people with HIV	5.45	4.91	5.2	4.93	4.36	4.43	4.47
Death rate (per 100 person-years) in whole adult population	1.69	1.63	1.66	1.63	1.56	1.58	1.57
Death rate (per 100 person years) amongst people on ART who have virologically failed 1 st line (regardless of whether monitoring strategy has detected it)	9.94	7.5	8.66	7.62	5.53	5.79	5.85
Incidence of HIV (per 100 person years)	0.84	0.81	0.83	0.81	0.76	0.79	0.73

cps = copies; ART = antiretroviral therapy;